Contract facts
FederalNo full NAICS 541714 intel page yet. Browse NAICS intelligence
FILL/FINISH DOD AS03 ADJUVANT CLIN 1006E is a federal award for Barda - Aspr / Daappo / Barda Dcma held by Glaxosmithkline LLC. Estimated value $491K ($491K obligated). Current period of performance ends Aug 30, 2026. Place of performance: DURHAM NC.
Recompete timing
PublicCurrent PoP ends Aug 30, 2026 (9 days remaining). Agencies typically plan 12–18 months ahead — at 0.3 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordGlaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75A50125F61019?
75A50125F61019 (DoD FILL FINISH as03 adjuvant) is a Barda - Aspr / Daappo / Barda Dcma award with a potential value of $491K, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75A50125F61019?
Barda - Aspr / Daappo / Barda Dcma awarded 75A50125F61019 to Glaxosmithkline LLC (potential $491K).
Who is the incumbent on 75A50125F61019?
Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Aug 30, 2026.
When does Glaxosmithkline LLC’s 75A50125F61019 come up for recompete?
SCOUT tracks a period-of-performance end of Aug 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.